We evaluate the cardiac safety (primary endpoint) of DT (q21d x 8 cycles), given alone if HER2-negative MBC or in combination with weekly H (DT-H; H 4 mg/kg IV week 1, then 2 mg/kg weekly) if HER2-positive MBC as first-line chemotherapy in patients (pts) who received no prior adjuvant A (target = 46 pts/arm).
Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): preliminary results of the Eastern Cooperative Oncology Group Trial E3198 (Abstract)
BONETTI, MARCO;
2003
Abstract
We evaluate the cardiac safety (primary endpoint) of DT (q21d x 8 cycles), given alone if HER2-negative MBC or in combination with weekly H (DT-H; H 4 mg/kg IV week 1, then 2 mg/kg weekly) if HER2-positive MBC as first-line chemotherapy in patients (pts) who received no prior adjuvant A (target = 46 pts/arm).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
